Female Breast Cancer Clinical Trial
Official title:
Efficacy of Endocrine Therapy Compared to Chemotherapy as a Neoadjuvant Treatment for Patients With Hormone Receptor-positive and HER2-negative Breast Cancer.
Eligible patients will be divided into two groups; one will receive neoadjuvant endocrine therapy and the other one will receive neoadjuvant chemotherapy.
Status | Not yet recruiting |
Enrollment | 100 |
Est. completion date | August 1, 2025 |
Est. primary completion date | April 1, 2025 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Any histological type of invasive breast cancer. All grades of breast cancer (I, II, III). ER-positive and/or PR-positive, HER2-negative breast cancer. ER and/or PR level of positivity =34 % (score 4 according to modified Allred score). Clinical Stages: any T N1-3, or T2-4 any N, M0. Exclusion Criteria: - Hormone receptor positivity < 34%. inflammatory breast cancer Metastatic breast cancer. Recurrent breast cancer. Other malignancy. Unfit patients for chemotherapy. |
Country | Name | City | State |
---|---|---|---|
Egypt | amal Ali | Sohag |
Lead Sponsor | Collaborator |
---|---|
Sohag University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical response rate | The primary endpoint will be; The clinical response rate at the end of neoadjuvant treatment, as will be determined using caliper and MRI measurements according to the (RECIST) version 1.1. | 6 months | |
Secondary | pathological complete response | The rate of pathological complete response after surgery. | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02480933 -
Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens
|
N/A | |
Completed |
NCT05000502 -
Exercise, Gut Microbiome, and Breast Cancer: Increasing Reach to Underserved Populations
|
N/A | |
Not yet recruiting |
NCT04863833 -
Tomosymthesis for Breast Mass Lesion Characterization
|
||
Withdrawn |
NCT06145399 -
A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer
|
Early Phase 1 | |
Suspended |
NCT01320488 -
Breast Cancer in Young Women: Is it Different?
|
N/A | |
Recruiting |
NCT02089854 -
Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer
|
Phase 4 | |
Active, not recruiting |
NCT01741883 -
Side Effect Prevention Training (SEPT) for Nocebo Effects in Breast Cancer Patients
|
N/A | |
Recruiting |
NCT06144164 -
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
|
Phase 3 | |
Recruiting |
NCT06331793 -
Pulsed Electromagnetic Fields for Analgesia Post Mastectomy
|
N/A | |
Recruiting |
NCT05439499 -
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
|
Phase 3 | |
Terminated |
NCT03836872 -
Acupuncture for Joint Symptoms in Patients With Breast Cancer
|
N/A | |
Recruiting |
NCT06332976 -
PrefeRences And ChemoTherapy In Breast Cancer patiEnts
|
||
Completed |
NCT01671319 -
Dose Dense TC + Pegfilgrastim Support for Breast Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06092892 -
IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases
|
Phase 2 | |
Recruiting |
NCT05586256 -
Ultra-hypofractionated Radiotherapy in Breast Cancer Patients
|
||
Not yet recruiting |
NCT03153631 -
Female Sexual Dysfunction in Breast Cancer Patients
|
N/A | |
Active, not recruiting |
NCT03059875 -
Place of Comprehensive Geriatric Assessment in Patients ≥ 75 Years Care, With Breast Cancer, After Screening With FOG (Oncology Geriatric Filter)
|
N/A | |
Active, not recruiting |
NCT02088710 -
Expectations and Side Effects of Endocrine Therapy in Women With Breast Cancer
|
N/A | |
Terminated |
NCT01083641 -
Estrogen for Triple Negative Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05374161 -
An Intervention for Female Breast CANcer: Acceptance and Commitment Therapy (I-CAN-ACT) for Depression and Physical Pain
|
N/A |